France· FR:69491256
LIPOROSA 20 mg/10 mg, gélule
A medicinal product containing rosuvastatine zincique + ézétimibe, registered in France by DIFARMED (ESPAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ROSUVASTATINE ZINCIQUE + ÉZÉTIMIBE
- Manufacturer
- DIFARMED (ESPAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400949004416plaquette(s) formée(s) à froid polyamide aluminium PVC-Aluminium de 30 gélule(s)EUR 14.47
- cip133400949004423plaquette(s) formée(s) à froid polyamide aluminium PVC-Aluminium de 90 gélule(s)EUR 40.94
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rosuvastatine zincique + ézétimibe in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDELIPID PLUSEgis Pharmaceuticals PLC, Budapešť
- SpainALZIL PLUS 10 MG/10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAFerrer Internacional S.A.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- PolandCorosweraKrka, d.d., Novo mesto
- NetherlandsEklipo 10 mg/10 mg filmomhulde tablettenMedicair Bioscience Laboratories CY Limited
- SwitzerlandEzetimib Rosuvastatin axapharm
- NorwayRostezeEQL Pharma AB
- FinlandRosuvastatin/Ezetimib KrkaKRKA d.d. Novo mesto
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Arosuva Plus Ezetimib, Ezerosu
- Belgium · Cholecomb, Ezetimibe/Rosuvastatin Sandoz
- Bulgaria · Rosteza 10 Mg/10 Mg, Rosteza 20 Mg/10 Mg
- Cyprus · Celmantin Plus, Lipocomb
- Czechia · Delipid Plus, Refidoro
- Germany · Antilia, Ezehron Duo
- Estonia · Delipid Plus, Rosazimib
- Spain · Alzil Plus, Arrox Plus
- Finland · Rosuvastatin/Ezetimib Krka, Rosuvastatin/Ezetimibe Ratiopharm
- Greece · Celmantin Plus, Co-Rosuvador
- Croatia · Arosen, Co-Roswera
- Hungary · Co-Xeter, Delipid Plus
- Ireland · Lipocomb, Rosuvastatin/Ezetimibe Krka
- Italy · Aurozeb, Cholecomb
- Lithuania · Roselia, Sorvitimb
- Luxembourg · Cholecomb, Myrosor
- Latvia · Rosazimib, Rosulip
- Malta · Ezehron Duo, Lipocomb
- Netherlands · Ayadont, Cholecomb
- Norway · Rosteze, Rosuvastatin/Ezetimib Krka
- Poland · Coroswera, Ezehron Duo
- Portugal · Colroset, Lipocomb
- Romania · Co-Roswera, Lipocomb
- Slovenia · Refidoro, Rozor
- Slovakia · Lipocomb, Rosazimib
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae286f05-038f-4c0a-9b5b-95dd5774ed79 GET /v1/drugs/ae286f05-038f-4c0a-9b5b-95dd5774ed79?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69491256",
"date_amm": "2021-03-23",
"type_amm": "Autorisation d'importation parallèle",
"numero_ue": null,
"substance": "ROSUVASTATINE ZINCIQUE + ÉZÉTIMIBE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about rosuvastatine zincique + ézétimibe.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.